Newsletter | May 27, 2020

05.27.20 -- 4 Steps Takeda Discovered To Improve Patient-Physician Dialogue

Focus On Patients
Industry Insights
Why Now Is The Time To Evaluate New Clinical Trial Technology

Whether your trial isn’t starting for six months or has already started, assessing new solutions and adopting best practices through automation can streamline your operations and improve patient retention.

Top 5 Events That Can Impact Your Clinical Supply Chain

Review practical solutions for “small changes” in the clinical supply chain that can wreak havoc if not planned for in advance.

How To Boost Support To Sites With Digital Clinical Technologies During The COVID-19 Crisis And Beyond

From countless conversations with sponsors of all sizes and therapeutic areas, we know that many of the digital solutions previously viewed as “nice to have” for clinical trial optimization are now proving to be vital to support sites. Here are five areas where we have seen sponsors deploy digital clinical technologies to boost support to sites and enable innovative drug development to continue ― not only during the COVID-19 crisis but well into the future.

Successful Wearable Device Selection For The Evolving Clinical Trials Landscape

The number of wearable, connected medical devices (wearable devices) available for use in healthcare and clinical research has increased significantly over the past few years, making it difficult for clinical trial sponsors to determine which devices to use in their clinical trials. This white paper is an introduction to the emerging adoption of wearables in clinical trials.

Actigraphy For Alzheimers

Alzheimer’s disease is a cognitive impairment, but it can manifest itself in many detrimental ways including alterations in daytime activity levels, sleep quality, and awake/sleep patterns. Read how actigraphy can provide important data when studying patients with Alzheimer's disease.

CCDS Or Local Labeling, A Chicken-And-Egg Situation?

In this blog, UBC’s Dr. Luca Cariolato, senior safety scientist, speaks to the importance of developing a company core data sheet (CCDS) before local safety information.

U.S Clinical Labels 101: Steps To Ensure Accuracy

Determining a drug candidate’s probability of commercial success is a most significant phase in the drug development process. There is no room for error.

Trends In Clinical Development

We asked 329 respondents from sponsor organizations to share their thoughts about a variety of current trends in the clinical development space. We analyzed responses by company size to understand how perspectives of respondents at large sponsors (those spending over $1B annually on R&D) differ from those at non-large organizations. Respondents were provided a list of trend-related statements and asked to rate their level of agreement with each.

Guidance For Remote Monitoring For Sponsors And CROs

Guidance for implementing remote monitoring as a broad policy at the site level. In light of COVID-19, Veeva proposes that sites and sponsors take a risk-based approach to updating policies and study documents to include only critical elements needed in order to implement remote monitoring quickly while not introducing administrative burdens on teams.

New Paradigm For Clinical Management Systems

The usual approach of adding technology and headcount to manage today’s clinical trials is not sustainable or scalable. In this webinar, Nick Dyer (CEO, Catalyst Clinical Research), discusses the challenges his team has experienced with complex early-phase oncology studies, and why they chose Medidata’s CTMS to help Catalyst attain operational success.

Life Science Leader Magazine

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.